CIBC Asset Management’s BridgeBio Pharma BBIO Stock Holding History

CIBC Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$447K	Sell	5,995 -151	-2%	-$10.6K	﹤0.01%	866
2026 Q1	$456K	Hold	6,146	–	–	﹤0.01%	828
2025 Q4	$470K	Buy	6,146 +676	+12%	+$44.4K	﹤0.01%	818
2025 Q3	$284K	Hold	5,470	–	–	﹤0.01%	958
2025 Q2	$236K	Buy	+5,470	New	+$199K	﹤0.01%	1012
2021 Q4	–	Sell	-6,868	Closed	-$322K	–	1544
2021 Q3	$322K	Hold	6,868	–	–	﹤0.01%	979
2021 Q2	$419K	Hold	6,868	–	–	﹤0.01%	855
2021 Q1	$423K	Buy	6,868 +2,530	+58%	+$166K	﹤0.01%	838
2020 Q4	$308K	Buy	+4,338	New	+$209K	﹤0.01%	892

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

CIBC Asset Management's BBIO Position: Q2 2026 in Review

CIBC Asset Management reduced its BridgeBio Pharma (BBIO) stake by 2.5% in Q2 2026, selling an estimated $10.6K and leaving 5,995 shares worth $447K. The position accounts for ﹤0.01% of the portfolio, ranked #866.

CIBC Asset Management first reported a position in BBIO in Q4 2020 and has held it in 9 quarters since. The position peaked at $470K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

CIBC Asset Management held 5,995 shares of BridgeBio Pharma worth $447K as of Q2 2026.
CIBC Asset Management sold 151 BridgeBio Pharma shares in Q2 2026, an estimated $10.6K.
BridgeBio Pharma made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #866 holding.
CIBC Asset Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 9 quarters since.
CIBC Asset Management's BridgeBio Pharma position peaked at $470K in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.